Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA

This analysis highlights the durability of first-line nivolumab plus ipilimumab with limited chemotherapy in metastatic NSCLC, demonstrating sustained overall survival and long-term response across PD-L1 expression levels and histologies. The findings reinforce that the survival benefit observed in CheckMate 9LA is maintained in broader clinical practice, including patients with traditionally poorer prognostic features such as PD-L1–negative and squamous disease.